Molecular & Cellular Oncology · 2016 · 29 citations · 7 references
MedicineCancer BiologyOncologyChromatin BiologyMolecular OncologyTranscriptional RegulationCancer Cell SignalingChromatinEpigenetic Regulation In CancerMyc Family OncogenesOncogene AddictionTumor Suppressor GenesC-myc RegulationChromatin Remodeler ActivityMyc OncogenesMyc Proto-oncogeneMyc Transcriptional ActivationMyc-dependent Chromatin RemodelingTherapeutic Target IdentificationTherapeutic Targeting Of Myc
The c-MYC oncogene is deregulated in virtually all human tumors and therefore constitutes an attractive therapeutic target. We found that the chromatin remodeler BPTF is a c-MYC interactor required for c-MYC chromatin recruitment and transcriptional activity. Moreover, inhibition of BPTF delays tumor development both in vitro and in vivo and its levels positively correlate with c-MYC signatures in human tumors. We propose BPTF as a therapeutic target in c-MYC-addicted tumors.
7
Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukaemia
Mark A. Dawson, Rab K. Prinjha, Antje Dittmann et al. · Nature · 2011 · 1.5K citations · Full text
Modelling Myc inhibition as a cancer therapy
Laura Soucek, Jonathan R. Whitfield, Carla P. Martins et al. · Nature · 2008 · 811 citations · Full text
Medicine, Cancer Biology, Oncology +14
Binding of myc proteins to canonical and noncanonical DNA sequences.
T. Keith Blackwell, Jing Huang, Averil Ma et al. · Molecular and Cellular Biology · 1993 · 375 citations · Full text
Interaction with WDR5 Promotes Target Gene Recognition and Tumorigenesis by MYC
Lance R. Thomas, Qingguo Wang, Brian C. Grieb et al. · Molecular Cell · 2015 · 317 citations · Full text